ArticleThe oncologist2019

A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.

Do-Youn Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.